Literature DB >> 16767175

Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease.

Annika F M Haywood1, Brian E Staveley.   

Abstract

Parkinson's disease (PD) patients show a characteristic loss of motor control caused by the degeneration of dopaminergic neurons. Mutations in the genes that encode alpha-synuclein and parkin have been linked to inherited forms of this disease. The parkin protein functions as a ubiquitin ligase that targets proteins for degradation. Expression of isoforms of human alpha-synuclein in the Drosophila melanogaster nervous system forms the basis of an excellent genetic model that recapitulates phenotypic and behavioural features of PD. Using this model, we analysed the effect of parkin co-expression on the climbing ability of aging flies, their life span, and their retinal degeneration. We have determined that co-expression of parkin can suppress phenotypes caused by expression of mutant alpha-synuclein. In the developing eye, parkin reduces retinal degeneration. When co-expressed in the dopaminergic neurons, the ability to climb is extended over time. If conserved in humans, we suggest that upregulation of parkin may prove a method of suppression for PD induced by mutant forms of alpha-synuclein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16767175     DOI: 10.1139/g06-011

Source DB:  PubMed          Journal:  Genome        ISSN: 0831-2796            Impact factor:   2.166


  11 in total

1.  Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1.

Authors:  Frits Kamp; Nicole Exner; Anne Kathrin Lutz; Nora Wender; Jan Hegermann; Bettina Brunner; Brigitte Nuscher; Tim Bartels; Armin Giese; Klaus Beyer; Stefan Eimer; Konstanze F Winklhofer; Christian Haass
Journal:  EMBO J       Date:  2010-09-14       Impact factor: 11.598

2.  Stable isotope labeling and label-free proteomics of Drosophila parkin null mutants.

Authors:  Zhiyin Xun; Thomas C Kaufman; David E Clemmer
Journal:  J Proteome Res       Date:  2009-10       Impact factor: 4.466

Review 3.  Drosophila melanogaster in the study of human neurodegeneration.

Authors:  Frank Hirth
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-08       Impact factor: 4.388

4.  α-Synuclein Transgenic Drosophila As a Model of Parkinson's Disease and Related Synucleinopathies.

Authors:  Hideya Mizuno; Nobuhiro Fujikake; Keiji Wada; Yoshitaka Nagai
Journal:  Parkinsons Dis       Date:  2010-12-20

5.  Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.

Authors:  Anne-Sophie Van Rompuy; Marusela Oliveras-Salvá; Anke Van der Perren; Olga Corti; Chris Van den Haute; Veerle Baekelandt
Journal:  Mol Neurodegener       Date:  2015-06-23       Impact factor: 14.195

6.  Potentiation of neurotoxicity in double-mutant mice with Pink1 ablation and A53T-SNCA overexpression.

Authors:  Suzana Gispert; Nadine Brehm; Jonas Weil; Kay Seidel; Udo Rüb; Beatrice Kern; Michael Walter; Jochen Roeper; Georg Auburger
Journal:  Hum Mol Genet       Date:  2014-10-08       Impact factor: 6.150

7.  Brain transcriptome changes in the aging Drosophila melanogaster accompany olfactory memory performance deficits.

Authors:  Rodrigo Pacifico; Courtney M MacMullen; Erica Walkinshaw; Xiaofan Zhang; Ronald L Davis
Journal:  PLoS One       Date:  2018-12-21       Impact factor: 3.240

Review 8.  Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson's Disease.

Authors:  Daniel Aghaie Madsen; Sissel Ida Schmidt; Morten Blaabjerg; Morten Meyer
Journal:  Cells       Date:  2021-01-31       Impact factor: 6.600

9.  alpha-Synuclein and neuronal cell death.

Authors:  Mark R Cookson
Journal:  Mol Neurodegener       Date:  2009-02-04       Impact factor: 14.195

10.  The Bcl-2 homologue Buffy rescues α-synuclein-induced Parkinson disease-like phenotypes in Drosophila.

Authors:  P Githure M'Angale; Brian E Staveley
Journal:  BMC Neurosci       Date:  2016-05-18       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.